

Serologische Untersuchung von Blutspenden auf Antikörper gegen SARS-CoV-2 (SeBluCo-Studie) – Blutspendedienste unterstützen die Pandemieüberwachung

1. Böhmer, M.M.; Buchholz, U.; Corman, V.M.; Hoch, M.; Katz, K.; Marosevic, D.V.; Böhm, S.; Woudenberg, T.; Ackermann, N.; Konrad, R.; et al. Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: A case series. *Lancet Infect. Dis.* 2020, 20, 920–928.
2. Pratha, S; Fitzpatrick, MC; Zimmer, CF; Abdollahic, E; Juden-Kellyc, L, Moghadasc, SM; Singerd, BH; Galvania, AP. Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis. *PNAS* 2021 Vol. 118,34.
3. Gorny, D.; Harries, M.; Gloeckner, S.; Strengert, M.; Kerrinnes, T.; Heise, J.-K.; Maaß, H.; Ortman, J.; Kessel, B.; Kemmling, Y.; et al. SARS-CoV-2 seroprevalence in Germany. *Dtsch. Arztebl. Int.* 2021, 118, 824–831.
4. Pritsch, M.; Radon, K.; Bakuli, A.; Le Gleut, R.; Olbrich, L.; Guggenbühl Noller, J.G.; Saathoff, E.; Castelletti, N.; Gari, M.; Pütz, P.; et al. Prevalence and Risk Factors of Infection in the Representative COVID-19 Cohort Munich. *Int. J. Environ. Res. Public Health* 2021, 18, 3572.
5. Wachtler, B.; Müters, S.; Michalski, N.; Koschollek, C.; Albrecht, S.; Haller, S.; Hamouda, O.; Hövener, C.; Hoebel, J. Socioeconomic inequalities in the prevalence and perceived dangerousness of SARS-CoV-2 infections in two early German hotspots: Findings from a seroepidemiological study. *BMC Res. Notes* 2021, 14, 375.
6. Santos-Hövener, C.; Neuhauser, H.K.; Rosario, A.S.; Busch, M.; Schlaud, M.; Hoffmann, R.; Gößwald, A.; Koschollek, C.; Hoebel, J.; Allen, J.; et al. Serology- and PCR-based cumulative incidence of SARS-CoV-2 infection in adults in a successfully contained early hotspot (CoMoLo study), Germany, May to June 2020. *Eurosurveillance* 2020, 25, 2001752.
7. Stone, M.; Di Germanio, C.; Wright, D.J.; Sulaeman, H.; Dave, H.; Fink, R.V.; Notari, E.P.; Green, V.; Strauss, D.; Kessler, D.; et al. Use of US Blood Donors for National Serosurveillance of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies: Basis for an Expanded National Donor Serosurveillance Program. *Clin. Infect. Dis.* 2022, 74, 871–881.
8. Amirthalingam, G.; Whitaker, H.; Brooks, T.; Brown, K.; Hoschler, K.; Linley, E.; Borrow, R.; Brown, C.; Watkins, N.; Roberts, D.J.; et al. Seroprevalence of SARS-CoV-2 among Blood Donors and Changes after Introduction of Public Health and Social Measures, London, UK. *Emerg. Infect. Dis.* 2021, 27, 1795–1801.
9. Jespersen, S.; Mikkelsen, S.; Greve, T.; Kaspersen, K.A.; Tolstrup, M.; Boldsen, J.K.; Redder, J.D.; Nielsen, K.; Abildgaard, A.M.; Kolstad, H.A.; et al. Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Survey among 17 971 Healthcare and Administrative Personnel at Hospitals, Prehospital Services, and Specialist Practitioners in the Central Denmark Region. *Clin. Infect. Dis.* 2021, 73, e2853–e2860.
10. Jones, J.M.; Stone, M.; Sulaeman, H.; Fink, R.V.; Dave, H.; Levy, M.E.; Di Germanio, C.; Green, V.; Notari, E.; Saa, P.; et al. Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020–May 2021. *JAMA* 2021, 326, 1400–1409.
11. Slot, E.; Hogema, B.M.; Reusken, C.B.E.M.; Reimerink, J.H.; Molier, M.; Karregat, J.H.M.; Ijlst, J.; Novotný, V.M.J.; van Lier, R.A.W.; Zaaier, H.L. Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands. *Nat. Commun.* 2020, 11, 5744.
12. Fink, R.V.; Fisher, L.; Sulaeman, H.; Dave, H.; Levy, M.E.; McCann, L.; Di Germanio, C.; Notari, E.P.; Green, V.; Cyrus, S.; et al. How do we ... form and coordinate a national serosurvey of SARS-CoV-2 within the blood collection industry? *Transfusion* 2022, 62, 1321–1333.
13. Bajema, K.L.; Wiegand, R.E.; Cuffe, K.; Patel, S.V.; Iachan, R.; Lim, T.; Lee, A.; Moyse, D.; Havers, F.P.; Harding, L.; et al. Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020. *JAMA Intern. Med.* 2021, 181, 450–460.
14. SeroTracker. Available online: <https://serotracker.com/en/Explore> (accessed on 14 July 2023).
15. Bergeri, I.; Whelan, M.G.; Ware, H.; Subissi, L.; Nardone, A.; Lewis, H.C.; Li, Z.; Ma, X.; Valenciano, M.; Cheng, B.; et al. Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies. *PLoS Med.* 2022, 19.
16. Scheiblaue, H.; Nübling, C.M.; Wolf, T.; Khodamoradi, Y.; Bellinghausen, C.; Sonntagbauer, M.; Esser-Nobis, K.; Filomena, A.; Mahler, V.; Maier, T.J.; et al. Antibody response to SARS-CoV-2 for more than one year - Kinetics and persistence of detection are predominantly determined by avidity progression and test design. *J. Clin. Virol.* 2022, 146, 105052.
17. Lau, E.H.Y.; Tsang, O.T.Y.; Hui, D.S.C.; Kwan, M.Y.W.; Chan, W.-H.; Chiu, S.S.; Ko, R.L.W.; Chan, K.H.; Cheng, S.M.S.; Perera, R.A.P.M.; et al. Neutralizing antibody titres in SARS-CoV-2 infections. *Nat. Commun.* 2021, 12, 63.
18. Hofmann, N.; Grossegeisse, M.; Neumann, M.; Schaade, L.; Nitsche, A. Evaluation of a commercial ELISA as alternative to plaque reduction neutralization test to detect neutralizing antibodies against SARS-CoV-2. *Sci. Rep.* 2022, 12, 3549.
19. Wölfel, R.; Corman, V.M.; Guggemos, W.; Seilmaier, M.; Zange, S.; Müller, M.A.; Niemeyer, D.; Jones, T.C.; Vollmar, P.; Rothe, C.; et al. Virological assessment of hospitalized patients with COVID-2019. *Nature* 2020, 581, 465–469.

20. Robert Koch Institute. COVID-19 Dashboard 2023. Available online: <https://experience.arcgis.com/experience/478220a4c45448> (zugegriffen 30. Juni 2023).
21. Robert Koch Institute. COVID-19 Vaccinations in Germany. Available online: https://github.com/robert-koch-institut/COVID-19-Impfungen_in_Deutschland (zugegriffen 14. Juli 2023).
22. Offergeld, R.; Preußel, K.; Zeiler, T.; Aurich, K.; Baumann-Baretti, B.I.; Ciesek, S.; Corman, V.M.; Dienst, V.; Drosten, C.; Görg, S.; et al. Monitoring the SARS-CoV-2 Pandemic: Prevalence of Antibodies in a Large, Repetitive Cross-Sectional Study of Blood Donors in Germany—Results from the SeBluCo Study 2020–2022. *Pathogens* 2023, 12, 551.
23. Speybroeck, N.; Devleesschauwer, B.; Joseph, L.; Berkvens, D. Misclassification errors in prevalence estimation: Bayesian handling with care. *Int. J. Public Health* 2013, 58, 791–795.
24. Devleesschauwer, B.; Torgerson, P.; Charlier, J.; Levecke, B.; Praet, N.; Roelandt, S.; Smit, S.; Dorny, P.; Berkvens, D.; Speybroeck, N. Prevalence: Tools for Prevalence Assessment Studies; R Package Version 0.4.1. 2022. Available online: <https://cran.r-project.org/web/packages/prevalence/prevalence.pdf> (zugegriffen 14. Juli 2023).
25. Henns, L.; Scholz, T.; von Rhein, C.; Wieters, I.; Borgans, F.; Eberhard, F.J.; Zacharowski, K.; Ciesek, S.; Rohde, G.; Vehreschild, M.; et al. Analysis of Humoral Immune Responses in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *J Infect Dis.* 2021 Jan 4;223(1):56-61.
26. Jin, D.K.; Nesbitt, D.J.; Yang, J.; Chen, H.; Horowitz, J.; Jones, M.; Vandergaast, R.; Carey, T.; Reiter, S.; Russell, S.J.; et al. Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and “Reopening”. *PLoS ONE* 2021, 16, e0250319.
27. Sullivan, D.J.; Franchini, M.; Joyner, M.J.; Casadevall, A.; Focosi, D. Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources. *Nat. Commun.* 2022, 13, 6478.
28. Saeed, S.; Drews, S.J.; Pambrun, C.; Yi, Q.L.; Osmond, L.; O'Brien, S.F. SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada. *Transfusion* 2021, 61, 862–872.
29. Backhaus, I.; Hermsen, D.; Timm, J.; Boege, F.; Lübke, N.; Degode, T.; Göbels, K.; Dragano, N. SARS-CoV-2 seroprevalence and determinants of infection in young adults: A population-based seroepidemiological study. *Public Health* 2022, 207, 54–61.
30. Robert Koch Institute. COVID-19-Fälle nach Altersgruppe und Meldewoche. Available online: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Daten/Altersverteilung.html?nn=2386228 (zugegriffen 14. Juli 2023).
31. Vygen-Bonnet, S.; Koch, J.; Bogdan, C.; Harder, T.; Heining, U.; Kling, K.; Littmann, M.; Meerpohl, J.; Meyer, H.; Mertens, T.; et al. Beschluss und Wissenschaftliche Begründung der Ständigen Impfkommission (STIKO) für die COVID-19-Impfempfehlung. *Epid. Bull.* 2021, 2, 3–63.
32. Robert Koch Institute. Digital Vaccination Monitoring and Low-Aggregated Health Insurance Billing Data (nicht öffentlich); Robert Koch Institute: Berlin, Germany, 2022.
33. Statistisches Bundesamt. Gesundheitspersonal 2023. Available online: https://www.destatis.de/DE/Themen/Gesellschaft-Umwelt/Gesundheit/Gesundheitspersonal/_inhalt.html (zugegriffen 14. Juli 2023).
34. Atsma, F.; Veldhuizen, I.; Verbeek, A.; de Kort, W.; de Vegt, F. Healthy donor effect: Its magnitude in health research among blood donors. *Transfusion* 2011, 51, 1820–1828.
35. Tuite, A.R.; Fisman, D.; Abe, K.T.; Rathod, B.; Pasculescu, A.; Colwill, K.; Gingras, A.-C.; Yi, Q.-L.; O'Brien, S.F.; Drews, S.J. Estimating SARS-CoV-2 Seroprevalence in Canadian Blood Donors, April 2020 to March 2021: Improving Accuracy with Multiple Assays. *Microbiol. Spectr.* 2022, 10, e02563-21.
36. Di Stefano, M.; Sarno, M.; Faleo, G.; Mohamed, A.M.F.; Lipsi, M.R.; De Nittis, R.; Bruno, S.R.; De Feo, L.; Granato, T.; Corso, G.; et al. Low Prevalence of Antibodies to SARS-CoV-2 and Undetectable Viral Load in Seropositive Blood Donors from South-Eastern Italy. *Acta Haematol.* 2021, 144, 580–584.
37. Dopico, X.C.; Muschiol, S.; Christian, M.; Hanke, L.; Sheward, D.J.; Grinberg, N.F.; Rorbach, J.; Bogdanovic, G.; Mcinerney, G.M.; Allander, T.; et al. Seropositivity in blood donors and pregnant women during the first year of SARS-CoV-2 transmission in Stockholm, Sweden. *J. Intern. Med.* 2021, 290, 666–676.
38. Neuhauser, H.; Rosario, A.S.; Butschalowsky, H.; Haller, S.; Hoebel, J.; Michel, J.; Nitsche, A.; Poethko-Müller, C.; Prütz, F.; Schlaud, M.; et al. Nationally representative results on SARS-CoV-2 seroprevalence and testing in Germany at the end of 2020. *Sci. Rep.* 2022, 12, 19492.
39. Reimer, T.; Horn, P.A.; Fischer, J.; Kordelas, L.; Jiménez Klingberg, C.L.; Zeiler, T. Andere Gene—Gleiche Chancen. *Hämotherapie* 2018, 31, 38–40.
40. O'Brien, S.F.; Drews, S.J.; Lewin, A.; Russell, A.; Davison, K.; Goldman, M. How do we decide how representative our donors are for public health surveillance? *Transfusion* 2022, 62, 2431–2437.
41. Lewin, A.; Osioy, C.; Erikstrup, C.; Custer, B.; Renaud, C.; Tiberghien, P.; Russell, A.; Lieshout-Krikke, R.; O'Brien, S.F. Research partnerships between blood services and public health authorities: An international, cross-sectional survey. *Vox Sang.* 2022, 117, 1368.